ACHD/Valve disease/Pericardial disease/Cardiomyopathy

THE ROLE OF THE ELECTROCARDIOGRAPHIC PHENOTYPE IN RISK STRATIFICATION FOR SUDDEN CARDIAC DEATH IN CHILDHOOD HYPERTROPHIC CARDIOMYOPATHY

1Constantin-Cristian Topicorean, 2Gabrielle Norrish, 3Chen Qu, 4Elia Fiend, 5Helen Walsh, 6Lidia Zielinska, 7Jacco Olivero, 8Silvia Passantino, 9Silvia Favilli, 10Anis Anastacki, 11Vasiliki Viagkouli, 12Robert Weintraub, 13Ingrid King, 14Elena Biajini, 15Lucas Ragni, 16Terence Prendiville, 17Sophie Duglan, 18Karen MLeod, 19Maria Iliia, 20Adrián Fernández, 21Regina Bökenkamp, 22Arnas Baban, 23Ongbo Drago, 24Peter Kubul, 25Piers Daubeny, 26Ian Chivers, 27Georgia Sargarella-Brupada, 28Sergi Cesar, 29Chiara Mannoni, 30Constanzzo Medrano, 31Garcia-Roves Reyes, 32Orhan Uzun, 33Feran Gran Ipira, 34Jose Castro Garcia, 35Javier Ramón Gimeno, 36Roberto Barriales-Villa, 37Fernando Rueda, 38Satish Advani, 39Jonathan Searle, 40Tara Bhuruka, 41Anna Siles, 42Ana Usano, 43Torsten Bloch Rasmussen, 44Caroline Jones, 45Kubo, 46Jens Mogensen, 47Zdenka Reinhardt, 48Elina Cervi, 49Penny Elliott, 50Rumana Omar, 51Jens Kaski. 1Institute of Cardiovascular Science, University College London, UK; 2Centre for Inherited Cardiovascular diseases, Great Ormond Street Hospital, London, UK; 3Department of Statistical science, University College London; 4Department of Cardiology, The Children’s Memorial Health Institute, Warsaw, Poland; 5Careggi University Hospital, Florence, Italy; 6Cardiology Unit, A Meyer Pediatric Hospital, Florence, Italy; 7Onassis Cardiac surgery center, Athens, Greece; 8The Royal Children’s Hospital, Melbourne, Australia; 9The Murdoch Children’s Research Institute; 10Oncology-Malbigi Hospital, Bologna, Italy; 11Our Lady’s Children’s Hospital, Dublin, Ireland; 12Royal Hospital for Children, Glasgow; 13Salvador Foundation University Hospital, Buenos Aires, Argentina; 14Leiden University Medical Center, Leiden, Netherlands; 15Bambino Gesu Hospital, Rome, Italy; 16University Hospital Motol, Prague, Czech Republic; 17Royal Brompton and Harefield NHS Trust, London, UK; 18Arrhythmia and Inherited Cardiac Diseases Unit, Hospital Sant Joan de Déu, University of Barcelona, 19Papa Giovanni XXIII hospital, Bergamo, Italy; 20Hospital General Universitario Gregorio Marañón, Madrid, Spain; 21University Hospital of Wales, Cardiff, UK; 22Val d’Hebron University Hospital, Barcelona, Spain; 23University Hospital Virgen de la Amica en Mora, Murcia, Spain; 24Complexo Hospitalario Universitario A Coruña, CIBERCV. A Coruña, Spain; 25John Radcliffe Hospital, Oxford, UK; 26Southampton general Hospital, Southampton, UK; 27Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV Madrid, Spain; 28Department of cardiology, Aarhus University Hospital, Aarhus, Denmark; 29Piler Hey Children’s hospital, Liverpool, UK; 30Department of Cardiology and Genetis, Kochi Medical School, Kochi University, Japan; 31Odense University Hospital, Odense, Denmark; 32The Freeman Hospital, Newcastle, UK; 33St Bartholomew’s Centre for Inherited Cardiovascular Diseases, St Bartholomew’s Hospital, West Smith

Introduction Sudden cardiac death is the most common cause of mortality in childhood onset hypertrophic cardiomyopathy, Identifying individuals at highest risk is therefore an essential part of clinical care but remains challenging. The 12 lead electrocardiogram (ECG) has been proposed as a useful tool for risk stratification and an ECG risk score has been proposed. However, this has not been independently validated and the ECG phenotype of childhood HCM has not been previously described. The aim of this study was to describe the ECG phenotype of childhood HCM in a large, international, multi-centre cohort and investigate its role in risk prediction for arrhythmic events.

Methods Participants with an available baseline resting 12-lead ECG were identified from a large, international, multi-centre, retrospective cohort of patients aged less than 16 years fulfilling the diagnostic criteria for HCM (n=1029). Resting baseline ECG was evaluated and ECG variables were extracted. In addition, the ECG risk score based on 8 parameters (deviation in QRS axis, pathological T-wave inversion in limb or preordial leads, ST-segment depression, dominant S-wave in V4, limb-lead amplitude sum, 12-lead amplitude duration product and QTc) was calculated as previously described. The primary study endpoint was a composite outcome of major cardiac events (MACE) defined as SCD, resuscitated cardiac arrest, appropriate implantable cardioverter defibrillator therapy, or sustained ventricular tachycardia (VT) with haemodynamic compromise. The discriminatory performance of using an ECG risk score >5 to identify patients at increased risk of MACE at 5 years was determined using Harrell’s C-index.

Results Of 356 patients with childhood HCM (68.9% male, mean age at presentation 10.1 ± 4.5 years), 347 (97.5%) had baseline ECG abnormalities such as: repolarization abnormalities (n=277, 77.8%), left ventricular hypertrophy (n=240, 67.6%), abnormal QRS axis (n=126, 35.4%) or QT prolongation (n=131, 36.8%). Over a median follow up of 3.9 years (IQR 2.0-7.7), 25 (7%) had an arrhythmic event, with an overall annual event rate of 1.38 (95% CI 0.93-2.04). No ECG variables were associated with 5-year MACE on univariable or multivariable Cox regression analysis. Of the 164 participants with an ECG score >5, 153 (93.3%) did not have a MACE within 5 years. Harrell’s C-index (the probability of correctly distinguishing between high and low risk patients using an ECG risk score threshold of >5) was 0.60 (95% CI 0.484-0.715) at 5 years. The corresponding positive and negative predictive values were 6.7% (95% CI 4.7 – 9.4%) and 96.9% (95% CI 94.2 – 98.4%).

Conclusions In a large, international, multi-centre cohort of children with HCM, ECG abnormalities are common. No ECG characteristic, either in isolation or combined in the ECG risk score, was associated with 5-year MACE risk. This suggests that the role of the baseline ECG phenotype in improving risk stratification in childhood HCM is limited. Conflict of Interest None

DIFFERENTIAL EFFECTS OF LEFT VENTRICULAR HYPTERTROPHY ON CORONARY HAEMODYNAMICS IN AORTIC STENOSIS AND HYPERTENSION

1Anenta Ramakrishnan, 2Nearchos Hadjiloizou, 3Yousif Ahmad, 4Sayan Sen, 5Iqbal Malik, 6Kim Parker, 7Darrel Francis, 8Alan Hughes, 9Jamil Mayet. 1Imperial College London, London, UK; 2Imperial College Healthcare NHS Trust

Background Hypertension and aortic stenosis(AS) are the commonest causes of left ventricular hypertrophy (LVH) and share similar pathophysiological features. Whilst an increase in resting coronary blood flow (per gram of LV) has been observed in AS, reduced resting coronary blood flow (per gram of LV) has been observed in hypertension.

Aim We aimed to compare coronary flow patterns in subjects with left ventricular hypertrophy and aortic stenosis, in subjects with left ventricular hypertrophy and hypertension, and in subjects without left ventricular hypertrophy or hypertension.

Methods We recruited 31 subjects (mean age 63, 18 female). 10 subjects had LVH and severe AS, 11 had LVH and hypertension and 10 had no LVH and no AS, with LVH defined on echocardiography. Simultaneous invasive pressure and Doppler velocity measurements in each of the left coronary arteries were taken. We performed ‘wave intensity analysis’, which is a method for

10.1136/heartjnl-2021-BCS.1
10.1136/heartjnl-2021-BCS.2
separating the coronary flow pattern in terms of ‘waves’ that are generated proximally (by the aorta and systemic arteries) and distally (by the myocardial microcirculation).

**Results**
Mean resting coronary flow per gram of tissue (figure 1) was increased in participants with LVH secondary to AS (1.62±0.60ml/min/g) and reduced in participants with LVH secondary to HT (0.49±0.27ml/min/g), compared to participants with no LVH and no AS (1.47±0.73ml/min/g).

Wave 6 (figure 2) is the backwards decompression wave (BDW) and is particularly important for myocardial perfusion. The BDW corresponds to the diastolic ‘suction’ of blood down the coronary arteries during myocardial relaxation.

The energy of the BDW was increased in LVH secondary to AS (31.1 x10^3Wm^-2s^-2) but was reduced in LVH secondary to HT (12.3x10^3Wm^-2s^-2) (p<0.05), compared to participants with no LVH and no AS (14.3x10^3Wm^-2s^-2).

The energy of the BDW correlated with LV cavity pressure (r=0.84, p<0.001) and diastolic time (r=-0.62, p<0.001) only in LVH secondary to AS participants. In contrast, the BDW correlated with LV mass (r=-0.49, p=0.03) in participants with LVH secondary to HT and with no LVH and no AS, but not in participants with LVH secondary to AS.

**Conclusions**
In hypertension, LVH is associated with reduced mean coronary flow and reduced myocardial ‘suction’ during diastole.

However, in AS, the large pressure gradient between the LV cavity pressure and the aorta results in a large contractile force which is generated in systole and then released in diastole. This large diastolic force overcomes any local impairment caused by the hypertrophied myocardium and contributes to high resting coronary flow in LVH that is secondary to AS, compared to LVH that is secondary to hypertension.

**Conflict of Interest**
None